VYNE Therapeutics Inc. Common Stock
Here’s whether VYNE Therapeutics Inc. Common Stock (VYNE) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Bearish.
Positives: 50-day MA is rising (+3.39% over 10 days); RSI 40 — healthy momentum range. Concerns: trading below the 200-day MA (long-term downtrend); below the 50-day MA (medium-term momentum negative); weak 1-year return of -62.0%; 3-month momentum negative (-21.1%); rising volume on a downtrend (distribution, 1.60x avg). Currently 68.1% off its 52-week high. Score: -3/7.
VYNE is trading below its 200-day MA ($0.56) — a key warning sign the longer-term trend is under pressure. An RSI of 40.0 sits in the neutral zone — momentum is neither stretched nor exhausted. The 1-year return of -62.0% compares to +16.5% for SPY (trailed the market by 78.5%). The current 68.1% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.